IMM 2510
Alternative Names: IMM-2510; SYN-2510Latest Information Update: 20 Sep 2024
At a glance
- Originator ImmuneOnco Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 17 Sep 2024 ImmuneOnco Biopharmaceuticals plans a phase II trial for Non-small cell lung cancer (Monotherapy, Second line therapy or greater)
- 16 Sep 2024 ImmuneOnco Biopharmaceuticals announces intention to submit IND to USFDA for Non-small cell lung cancer in 2024
- 16 Sep 2024 ImmuneOnco Biopharmaceuticals plans a phase Ib/II trial in Non-small cell lung cancer (Combination therapy, First-line therapy) in China in 2024